EU MDR and IVDR Compliance Update: What Medical Device Manufacturers Need to Know

As of September 2025, EU MDR 2017/745 is fully in effect for the vast majority of device categories, with the limited transition provisions for legacy MDD-certified devices approaching their final deadlines. EU IVDR 2017/746 is similarly advancing through its phased implementation, with Class D IVDs having faced the earliest mandatory compliance dates and lower-risk classes following on a rolling schedule. Manufacturers who have not yet completed their MDR and IVDR transitions face an increasingly narrow window before loss of market access in the EU becomes a practical reality.

EU MDR Status in 2025

The most significant active transition consideration under EU MDR is the fate of devices that were CE marked under the Medical Device Directive (MDD) or Active Implantable Medical Device Directive (AIMDD) and have been relying on the transitional provisions introduced by EU Regulation 2023/607. Under the extended timeline, MDD/AIMDD certificates issued before May 26, 2021 can remain valid until:

• December 31, 2027 for Class III and Class IIb implantable devices
• December 31, 2028 for Class IIa, Class IIb non-implantable, and Class I devices requiring notified body involvement

However, these extended deadlines are conditional: manufacturers must have a valid MDR application lodged with a notified body before May 26, 2024, and must maintain continuous compliance with the MDD for the duration of the transition. Manufacturers who missed the May 2024 lodging deadline have lost access to the extended timelines and must prioritize urgent MDR certification activities.

EU IVDR Phase-In Timeline

The IVDR phase-in timeline was extended by EU Regulation 2022/112, creating a staggered implementation schedule based on device class. Class D IVDs (highest risk, such as HIV and hepatitis tests) faced a mandatory compliance date of May 26, 2025. Class C IVDs face a deadline of May 26, 2026, and Class B and Class A sterile IVDs face deadlines of May 26, 2027 and 2028 respectively. Self-tests in the lower risk classes have additional time. Manufacturers of IVDs who have not yet initiated notified body engagement for their Class C and D products should treat this as an immediate priority given the notified body capacity constraints documented across the EU IVD sector.

Key Technical Documentation Differences from Legacy Directives

Manufacturers transitioning from MDD or AIMD CE marking often underestimate the substantive differences in technical documentation requirements between the legacy directives and the MDR. The most impactful changes include the requirement for a Clinical Evaluation Report (CER) that demonstrates clinical evidence based on data from the specific device under review (not just equivalent devices), the mandatory Summary of Safety and Clinical Performance (SSCP) for implantable and Class III devices, and the significantly expanded post-market surveillance documentation requirements including PSURs. Manufacturers whose existing technical files were adequate under the MDD should not assume they will pass notified body scrutiny under MDR without substantial enhancement.

Notified Body Capacity and Audit Planning

Notified body capacity in the EU remains constrained relative to the volume of MDR applications in the system. Wait times for initial technical documentation reviews continue to vary significantly across notified bodies, with some reporting backlogs of 18 months or more for complex Class III submissions. Manufacturers should maintain proactive communication with their designated notified body, respond promptly to information requests, and avoid scope creep in their applications that could trigger additional review steps. Planning for a notified body audit cycle of at least 24 months from initial application to certificate issuance is prudent for complex devices.